Baylor team suggests new way to attack triple-negative breast cancer

In a paper published in Nature Medicine, researchers from Baylor College of Medicine and colleagues suggest that specifically targeting multiple RTKs regulated by protein tyrosine phosphatase non-receptor type 12 (PTPN12), a tumor suppressor frequently inactivated in triple-negative breast cancer, could help treat the disease.

Receptor tyrosine kinases (RTKs), which can promote tumor growth in TNBC, have been targeted to treat the disease. However, the authors wrote in the paper that RTK inhibitors have been largely ineffective in patients with TNBC, a particularly aggressive cancer...